Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s10194-018-0874-y http://scihub22266oqcxt.onion/10.1186/s10194-018-0874-y C6006000!6006000!29915913     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Headache+Pain 2018 ; 19 (1): ä Nephropedia Template TP {{tp|p=29915913|t=2018. OnabotulinumtoxinA in the treatment of refractory chronic cluster headache |pdf=|usr=}}{{29915913}} gab.com Text OnabotulinumtoxinA in the treatment of refractory chronic cluster headache JO: J Headache Pain http://www.kidney.de/pget.php?&tw=1&pmid=29915913 #FOAvip Background: Cluster headache (CH) is a clinically well-defined primary headache disorder, approximately 20% of cluster headache sufferers experience recurrent attacks without periods of significant remission. For the treatment of chronic cluster headache (CCH) only limited therapeutic options are available. Methods: A potential refractory CCH patient group was identified according to the clinical definition of rCCH based on the consensus statement of the European Headache Federation (EHF). Treatment with OnabotulinumtoxinA (BoNT-A; Botox®, 150 Allergan IU) was done according to the PREEMPT study protocol. A standardized headache diary was used for recording frequency, duration of attacks and pain intensity. To assess personal burden the HIT-6 and the Hospital Anxiety and Depression scale was used. Primary outcome measure was a?>?50% reduction in headache minutes. Results: Seventeen male patients suffering from rCCH, aged 32?±?11 (mean?±?SD) years, presenting a mean disease duration of 6.6 years completed the study of 28 weeks. The cut-off point of >?50% reduction in headache minutes as positive result was reached in 58.8%, 29.4% experienced an improvement of 30?50%. Mean frequency of headache days dropped from 28.2 to 11.8 days at week 24 (p =?0.0001; 95% CI -21.33 to ??11.61;). Intensity of remaining attacks was also reduced significantly. Headache disability scores showed a trend to improvement after BoNT-A. Conclusions: Encouraging results for the treatment with BoNT-A in rCCH patients were observed in our study population. Twit Text FOAVip OnabotulinumtoxinA in the treatment of refractory chronic cluster headache ????J Headache Pain http://www.kidney.de/pget.php?&tw=1&pmid=29915913 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29915913 #FOAvip English Wikipedia <ref>{{Cite pmid|29915913}}</ref> OnabotulinumtoxinA in the treatment of refractory chronic cluster headache #MMPMID29915913 Lampl C; Rudolph M; Bräutigam E J Headache Pain 2018[]; 19 (1): ä PMID29915913show ga Background: Cluster headache (CH) is a clinically well-defined primary headache disorder, approximately 20% of cluster headache sufferers experience recurrent attacks without periods of significant remission. For the treatment of chronic cluster headache (CCH) only limited therapeutic options are available. Methods: A potential refractory CCH patient group was identified according to the clinical definition of rCCH based on the consensus statement of the European Headache Federation (EHF). Treatment with OnabotulinumtoxinA (BoNT-A; Botox®, 150 Allergan IU) was done according to the PREEMPT study protocol. A standardized headache diary was used for recording frequency, duration of attacks and pain intensity. To assess personal burden the HIT-6 and the Hospital Anxiety and Depression scale was used. Primary outcome measure was a?>?50% reduction in headache minutes. Results: Seventeen male patients suffering from rCCH, aged 32?±?11 (mean?±?SD) years, presenting a mean disease duration of 6.6 years completed the study of 28 weeks. The cut-off point of >?50% reduction in headache minutes as positive result was reached in 58.8%, 29.4% experienced an improvement of 30?50%. Mean frequency of headache days dropped from 28.2 to 11.8 days at week 24 (p =?0.0001; 95% CI -21.33 to ??11.61;). Intensity of remaining attacks was also reduced significantly. Headache disability scores showed a trend to improvement after BoNT-A. Conclusions: Encouraging results for the treatment with BoNT-A in rCCH patients were observed in our study population. äOnabotulinumtoxinA in the treatment of refractory chronic cluster head(epmc).pdf DeepDyve Pubget Overpricing